Document is current
Any future updates will be listed below
-
Authors
Ajay Castro, Sowmya https://orcid.org/0000-0001-9831-2907
Passmore, Ian J.
Ndeh, Didier
Shaw, Helen Alexandra https://orcid.org/0000-0002-1129-2075
Ruda, Alessandro
Burns, Keira
Thomson, Sarah
Nagar, Rupa https://orcid.org/0000-0003-2127-3115
Alagesan, Kathirvel
Reglinski, Mark
Lucas, Kieron
Abouelhadid, Sherif
Schwarz-Linek, Ulrich
Mawas, Fatme
Widmalm, Göran https://orcid.org/0000-0001-8303-4481
Wren, Brendan W. https://orcid.org/0000-0002-6140-9489
Dorfmueller, Helge C. https://orcid.org/0000-0003-1288-044X
- License Information
-
More Information
Article History
Received: 27 March 2024
Accepted: 6 January 2025
First Online: 22 January 2025
Competing interests
: The author HCD holds a patent on the rhamnose polysaccharide platform technology (WO2020249737A1). BWW and SA hold a patent for the E. coli strain used in this study (US20150344928A1). BWW is co-founder of ArkVax Ltd., a company that has an exclusive licence to the ‘MAGIC technology’ (patent number US20150344928A1). All other authors declare no competing interests.
